Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
December 2024 CLL Bloodline – Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
CLL patient Mark Silverstein passed away after his cancer turned to Richter’s transformation. His widow shared his unfinished reflection on his diagnosis.
Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.
A variety of tests are used to capture images inside the body when chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are present.
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
One year after Dr. Brian Koffman enrolled as the first chronic lymphocytic leukemia (CLL) patient in the epcoritamab clinical trial, all is well.
CLL Society awarded Dr. Prajish Iyer a research grant for his project studying Richter’s transformation, a rare but aggressive progression of CLL.
One click to our most popular content.
